JP2005502327A - ヘラオオバコ花粉の主要アレルゲンのＰｌａｌ１をコードする組換えＤＮＡ及びその適用 - Google Patents
ヘラオオバコ花粉の主要アレルゲンのＰｌａｌ１をコードする組換えＤＮＡ及びその適用 Download PDFInfo
- Publication number
- JP2005502327A JP2005502327A JP2003500121A JP2003500121A JP2005502327A JP 2005502327 A JP2005502327 A JP 2005502327A JP 2003500121 A JP2003500121 A JP 2003500121A JP 2003500121 A JP2003500121 A JP 2003500121A JP 2005502327 A JP2005502327 A JP 2005502327A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- sequence
- pla
- peptide
- allergen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013566 allergen Substances 0.000 title claims abstract description 131
- 235000003805 Musa ABB Group Nutrition 0.000 title description 13
- 235000015266 Plantago major Nutrition 0.000 title description 13
- 108020004511 Recombinant DNA Proteins 0.000 title description 4
- 240000008790 Musa x paradisiaca Species 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 98
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 91
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 58
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 29
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 27
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 27
- 239000012634 fragment Substances 0.000 claims abstract description 21
- 230000000295 complement effect Effects 0.000 claims abstract description 5
- 238000004925 denaturation Methods 0.000 claims abstract description 3
- 230000036425 denaturation Effects 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 49
- 208000026935 allergic disease Diseases 0.000 claims description 44
- 230000007815 allergy Effects 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 39
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 239000002773 nucleotide Substances 0.000 claims description 32
- 125000003729 nucleotide group Chemical group 0.000 claims description 32
- 235000003421 Plantago ovata Nutrition 0.000 claims description 31
- 239000009223 Psyllium Substances 0.000 claims description 31
- 229940070687 psyllium Drugs 0.000 claims description 31
- 241000196324 Embryophyta Species 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 9
- 239000013612 plasmid Substances 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 208000030961 allergic reaction Diseases 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000002255 vaccination Methods 0.000 claims description 4
- 208000010216 atopic IgE responsiveness Diseases 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- 241001499741 Plantago arenaria Species 0.000 claims 3
- 241000795633 Olea <sea slug> Species 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 74
- 229960004784 allergens Drugs 0.000 description 49
- 239000002299 complementary DNA Substances 0.000 description 29
- 244000134552 Plantago ovata Species 0.000 description 28
- 239000000203 mixture Substances 0.000 description 18
- 229960005486 vaccine Drugs 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 241001127637 Plantago Species 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 230000000172 allergic effect Effects 0.000 description 11
- 208000010668 atopic eczema Diseases 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 241000013557 Plantaginaceae Species 0.000 description 9
- 244000239204 Plantago lanceolata Species 0.000 description 9
- 235000010503 Plantago lanceolata Nutrition 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 241000235058 Komagataella pastoris Species 0.000 description 7
- 229940074608 allergen extract Drugs 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 102100036826 Aldehyde oxidase Human genes 0.000 description 5
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 5
- 108091036066 Three prime untranslated region Proteins 0.000 description 5
- 230000002009 allergenic effect Effects 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 238000010804 cDNA synthesis Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 240000007817 Olea europaea Species 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000013573 pollen allergen Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- -1 QuilA Chemical class 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 206010048908 Seasonal allergy Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000005546 dideoxynucleotide Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 108091005573 modified proteins Proteins 0.000 description 3
- 102000035118 modified proteins Human genes 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012232 AGPC extraction Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- 208000012657 Atopic disease Diseases 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 235000018185 Betula X alpestris Nutrition 0.000 description 2
- 235000018212 Betula X uliginosa Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241001465875 Coronopus Species 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 235000002725 Olea europaea Nutrition 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 2
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 2
- 101800000684 Ribonuclease H Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 208000028004 allergic respiratory disease Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000001142 circular dichroism spectrum Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 201000004335 respiratory allergy Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 1
- QZCJOXAIQXPLNS-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4a,5,5,6,6,7,7,8,8,8a-octadecafluoronaphthalene 4-(2-aminoethyl)benzene-1,2-diol Chemical compound NCCc1ccc(O)c(O)c1.FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F QZCJOXAIQXPLNS-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 101150061183 AOX1 gene Proteins 0.000 description 1
- 101150006240 AOX2 gene Proteins 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 235000006760 Acer pensylvanicum Nutrition 0.000 description 1
- 240000002245 Acer pensylvanicum Species 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100162339 Anguilla japonica l-1 gene Proteins 0.000 description 1
- 241001325712 Arnoglossum Species 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 241000219430 Betula pendula Species 0.000 description 1
- TXNJAVCZNMSELK-UHFFFAOYSA-N CCCCCCCCCCCCOC(=O)CNC Chemical compound CCCCCCCCCCCCOC(=O)CNC TXNJAVCZNMSELK-UHFFFAOYSA-N 0.000 description 1
- 241000037164 Collema parvum Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101150069554 HIS4 gene Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001415864 Lagopus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010038049 Mating Factor Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241001644525 Nastus productus Species 0.000 description 1
- 241000207836 Olea <angiosperm> Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000013567 aeroallergen Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000010083 bronchial hyperresponsiveness Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 239000011436 cob Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- BDWFYHUDXIDTIU-UHFFFAOYSA-N ethanol;propane-1,2,3-triol Chemical compound CCO.OCC(O)CO BDWFYHUDXIDTIU-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940046528 grass pollen Drugs 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940071204 lauryl sarcosinate Drugs 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29467201P | 2001-05-30 | 2001-05-30 | |
| DKPA200100857 | 2001-05-30 | ||
| PCT/DK2002/000362 WO2002096942A2 (en) | 2001-05-30 | 2002-05-29 | Recombinant dna encoding the major allergen of plantago lanceolata pollen pla l 1, and applications thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005502327A true JP2005502327A (ja) | 2005-01-27 |
| JP2005502327A5 JP2005502327A5 (enExample) | 2006-01-05 |
Family
ID=26069030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003500121A Pending JP2005502327A (ja) | 2001-05-30 | 2002-05-29 | ヘラオオバコ花粉の主要アレルゲンのＰｌａｌ１をコードする組換えＤＮＡ及びその適用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040071717A1 (enExample) |
| EP (1) | EP1425396A2 (enExample) |
| JP (1) | JP2005502327A (enExample) |
| CN (1) | CN1596309A (enExample) |
| CA (1) | CA2449127A1 (enExample) |
| WO (1) | WO2002096942A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006308411A (ja) * | 2005-04-28 | 2006-11-09 | Asahi Breweries Ltd | 花粉症の検査または評価方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2388268A1 (en) * | 2010-05-18 | 2011-11-23 | Stallergenes S.A. | Recombinant Der p 2 expressed in Pichia pastoris as a "natural-like" allergen for immunotherapy and diagnostic purposes |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2125201B1 (es) * | 1997-06-24 | 2000-03-16 | Bial Ind Farmaceutica S A | Adn recombinante que codifica para epitopos del alergeno mayor de olea europaea ole e 1 util para el diagnostico y tratamiento de alergias. |
-
2002
- 2002-05-29 CN CNA028130006A patent/CN1596309A/zh active Pending
- 2002-05-29 WO PCT/DK2002/000362 patent/WO2002096942A2/en not_active Ceased
- 2002-05-29 CA CA002449127A patent/CA2449127A1/en not_active Abandoned
- 2002-05-29 EP EP02745174A patent/EP1425396A2/en not_active Withdrawn
- 2002-05-29 JP JP2003500121A patent/JP2005502327A/ja active Pending
- 2002-09-03 US US10/161,551 patent/US20040071717A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006308411A (ja) * | 2005-04-28 | 2006-11-09 | Asahi Breweries Ltd | 花粉症の検査または評価方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002096942A2 (en) | 2002-12-05 |
| WO2002096942A3 (en) | 2004-03-25 |
| US20040071717A1 (en) | 2004-04-15 |
| EP1425396A2 (en) | 2004-06-09 |
| CA2449127A1 (en) | 2002-12-05 |
| CN1596309A (zh) | 2005-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Focke et al. | Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination | |
| JP2008214347A (ja) | 生物材料およびその使用 | |
| Hufnagl et al. | Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice | |
| JP4102432B2 (ja) | 杉花粉由来のアレルゲン性蛋白質及びペプチド | |
| AU2012277491B2 (en) | Contiguous overlapping peptides for treatment of ragweed pollen allergy | |
| JP2005502327A (ja) | ヘラオオバコ花粉の主要アレルゲンのＰｌａｌ１をコードする組換えＤＮＡ及びその適用 | |
| US9522939B2 (en) | Hypoallergenic chimeric proteins belonging to the lipid transfer family of Parietaria judaica for use in the treatment of allergies | |
| EP1317484B2 (en) | Variants of the phleum pratense phl p 1 allergenic protein | |
| RU2285042C2 (ru) | Новые мутантные аллергены | |
| US6214358B1 (en) | Protein allergens of the species Cynodon dactylon | |
| EP1219299B2 (en) | Allergy vaccines and their preparation | |
| US7514083B1 (en) | Protein allergens of the species cynodon dactylon | |
| WO1992016554A1 (en) | Protein allergens of the species cynodon dactylon | |
| JP2011236217A (ja) | 牧草花粉Ｐｈｌｐ６アレルゲンの非アナフィラキシー形態及びそれらの使用 | |
| AU2002316802A1 (en) | Recombinant DNA encoding the major allergen of Plantago lanceolata pollen Pla l 1, and applications thereof | |
| CN101861331B (zh) | 垂枝桦花粉主要变应原的低变应原性变体 | |
| HK1045810C (en) | Allergy vaccines and their preparation | |
| EP2794644B1 (en) | Hypoallergenic variants of phl p 5, the major allergen from phleum pratense | |
| EP2281836B1 (en) | Hybrid proteins from Parietaria judaica major allergens and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050526 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050526 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071022 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080324 |